ERBB2 and breast cancer: Studies including Only Specific BC Molecular Subtypes: Koh et al. [30] reported that in patients with hormone receptor-positive/HER2- negative BC, NLR was an independent prognostic factor for DFS (HR = 3.87; 95%CI 1.64–9.14; p = 0.002).